Company intelligence / Profile preview

Kerberos Biopharmaceuticals

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Kerberos Biopharmaceuticals is a pre-clinical stage biotechnology company spun out of the Drexel University College of Medicine. The company focuses on developing novel therapeutics to prevent and treat metastatic cancer, specifically targeting the chemokine receptor CX3CR1 (fractalkine receptor) and its role in tumor progression and metastasis. Its lead program, JMS-17-2, is a potent small-molecule antagonist of CX3CR1 designed to impair the lodging of circulating tumor cells to the skeleton and soft-tissue organs. Although the company demonstrated promising results in animal models of metastatic breast cancer, it has since become inactive (deadpooled).

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Kerberos Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kerberos Biopharmaceuticals.

Explore the full profile